Crossmark

ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Crossref DOI link: https://doi.org/10.1186/s12885-018-5134-7

Published Online: 2018-12-06

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Racioppi, Marco

Di Gianfrancesco, Luca

Ragonese, Mauro

Palermo, Giuseppe http://orcid.org/0000-0002-0564-7415
Sacco, Emilio

Bassi, Pier Francesco
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 3 April 2018

Accepted: 26 November 2018

First Online: 6 December 2018

Ethics approval and consent to participate

: The study was approved by the local ethics committee (Fondazione Policlinico “A. Gemelli” IRCSS, Rome, Italy – Università Cattolica del Sacro Cuore, Rome, Italy). The study involved human participants with their consent; the informed consent was written.

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below